Targeted biological treatment of solid tumours

Czech version

Authors: L. Petruželka ^1,2
Authors‘ workplace: Onkologická klinika 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Luboš Petruželka, CSc. ¹; Ústav radiační onkologie 1. lékařské fakulty UK a FN Na Bulovce Praha, přednosta prof. MUDr. Luboš Petruželka, CSc. ²
Published in: Vnitř Lék 2011; 57(9): 740-744
Category: 65th birthday Mudr. Jany Laciné and and 60th birthday Milana Tržila

Overview

Clinical use of targeted biological treatment was initiated in 1970s following a discovery of hormonal receptors and targeted clinical use of tamoxifen. Deeper understanding of molecular principles of the process of metastasizing and cell communication and signalling have contributed to the development of targeted molecular biological treatments based on direct impact on the key target structures of a tumour cell. Clinical effectiveness of targeted biological treatment has been shown in phase III clinical studies in advanced and metastasising solid tumours and importantly expanded our armamentarium of pharmacotherapeutic treatment options in breast cancer, colorectal cancer, non-small cell lung cancer, kidney cancer, hepatocellular carcinoma and gastrointestinal stromal tumour. Full implementation of targeted therapy is precluded by a lack of reliable predictors of efficacy of a number of targeted drugs. Therefore, full identification of such predictors is a subject to intensive clinical research. At present, selection of biological treatment is based on morphological, immunohistochemical and partly also molecular profile of a tumour. The future of biological treatment lies in a selection that is based on full molecular characterization of the primary tumour as well as metastasis.

Key words:
targeted biological treatment – prediction – biomarkers – treatment algorithm – individual treatment plan

Sources

1. Petruželka L. Pohled na vývoj onkologie ve 3. tisíciletí. Klin Onkol 2009; 22: 243–244.

2. Sawyers C. Targeted cancer therapy. Nature 2004; 432: 294–297.

3. Petruželka L, Novotný J, Závadová E. Principy molekulární bioregulační léčby. In: Cibula D, Petruželka L et al (eds). Onkogynekologie. Praha: Grada 2009.

4. Pink JJ, Jordan VC. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res 1996; 56: 2321–2330.

5. MacConaill LE, Garraway LA. Clinical Implications of the Cancer Genome. J Clin Oncol 2010; 28: 5219–5228.

6. Ramaswamy S, Perou CM. DNA microarrays in breast cancer: the promise of personalised medicine. Lancet 2003; 361: 1576–1577.

7. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002; 7 (Suppl 4): 2–8.

8. Stricker T, Catenacci DV, Seiwert TY. Molecular profilig of cancer – the future of personalized cancer medicine: a primer on cancer biology and tool necessary to bring molecular testing to the clinic. Semin Oncol 2011; 38: 173–185.

9. Petruželka L. Cílená molekulární biologická léčba karcinomu prsu. Referátový výběr z onkologie 2006; 23: 33–37.

10. Hanahan D, Weinberg RA. The Hallmarks of Cancer. Cell 2000; 100: 57–70.

11. Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell 2011; 144: 646–674.

12. Mountzios G, Soria JCH. Overview of Existing Therapies. In: Giaccone G, Soria JCH (eds). Targeted Therapies in Oncology. Informa healthcare 2007: 1–4.

13. Petruželka L, Petruželková L. Lapatinib. Farmakoterapie 2008; 4: 495–507.

14. Petruželka L. Cetuximab v první linii léčby kolorektálního karcinomu. Farmakoterapie 2008; 11: 320–321.

15. Gonzalez-Angulo AM, Hennessy BT, Mills GB. Future of Personalized Medicine in Oncology: A systems Biology Approach. J Clin Oncol 2010; 28: 2777–2783.

16. Schadt EE, Lamb J, Yang X et al. An integrative genomics approach to infer causal associations between gene expression and disease. Nat Genet 2005; 37: 710–717.

17. Tursz T, Fabrice AF, Lazar V et al. Implications of personalized medicine – perspective from a cancer center. Nat Rev Clin Oncol 2011; 8: 177–183.

18. Auffray C, Charron D, Hood L. Predictive, preventive, personalized and participatory medicine: back to the future. Genome Med 2010; 2: 57–58.

19. Innocenti F, Cox NJ, Dolan ME. The use of genomic information to optimize cancer chemotherapy. Semin Oncol 2011; 38: 186–195.

20. Mendelsohn J, Tursz T, Schilsky RL et al. Focus on personalized medicine: WIN Consortium – challenges and advances. Nat Rev Clin Oncol 2011; 8: 133–134.

21. Petruželka L. Necílené podávání cílené biologické léčby aneb proč nemusí platit, kdo léčí více nemocných, léčí lépe. Edukační sborník XIV. dne profesora Staška 2009: Editorial.